ArticleTheranostics2021
Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- PEGylated IL2 and tumor-targeted radiotherapy augment CD8Theranostics · 2026Trial
- Immunogenic Cell Death in Melanoma Induced by Radiotherapy, Photodynamic Therapy, or Non-Thermal Plasma: The Role of Reactive Oxygen and Nitrogen Species.Biomedicines · 2026Review
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models.Cancer immunology research · 2026Article
- Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.Journal for immunotherapy of cancer · 2026Article
- Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.Journal of experimental & clinical cancer research : CR · 2026Article
- Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice.Nature communications · 2026Article
- Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Frontiers in oncology · 2026Review
- The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy.Military Medical Research · 2026Review
- Immunosenescence modulates radiation-induced anti-tumor immunity: implications for personalized immuno-oncology.Frontiers in immunology · 2026Review
- Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges.Frontiers in pharmacology · 2026Review
- Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based β-emitting targeted radionuclide therapy across tumor immunogenicity profiles.Frontiers in immunology · 2026Article
- Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models.Science advances · 2025Article
- LiposomalCancer science · 2025Article
- Review
- The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy.Cancer immunology research · 2025Article
- Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.International journal of molecular sciences · 2025Review
- Low-dose radiation by radiopharmaceutical therapy enhances GD2Science advances · 2025Article
- Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.Cell communication and signaling : CCS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 1 institution in 1 country.
Justin C JagodinskyDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Won Jong JinDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Amber M BatesDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Reinier HernandezDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Joseph J GrudzinskiDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Ian R MarshDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Ishan ChakravartyDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Ian S ArthurDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Luke M ZanglDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Ryan J BrownDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Erin J NystuenDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Sarah E EmmaDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Caroline KerrDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Peter M CarlsonDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Raghava N SriramaneniDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Jonathan W EngleDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Eduardo Aluicio-SarduyDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Todd E BarnhartDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Trang LeDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
KyungMann KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Bryan P BednarzDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Jamey P WeichertDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Ravi B PatelDepartment of Radiation Oncology, University of Pittsburgh School Hillman Cancer Center, Pittsburgh, PA.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
University of Wisconsin–Madison · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MRadionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2020 to 2024
$12.5MU.W. RADIOLOGICAL SCIENCES TRAINING PROGRAMT32CA009206 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Bryan Patrick Bednarz · 1985 to 2026
$12.1MProject 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MNRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4MImmunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0MGene Expression Analysis of Dog Natural Killer Cells Following Immunotherapy with Molecularly Targeted Radionuclide therapy or Inhaled IL-15U01CA224166 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CANTER, ROBERT J., MORRIS, ZACHARY SCOTT · 2017 to 2021
$3.0MCombining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9MUtilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sitesK08CA241319 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PATEL, RAVI BHASKER · 2019 to 2023
$629kUW SPECT/CT AcquisitionS10OD028670 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI WEICHERT, JAMEY P · 2020 to 2020
$598kNCATS NIH HHS TL1 TR002375NCI NIH HHS F30 CA250263NCI NIH HHS K08 CA241319NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS P30 CA047904NCI NIH HHS T32 CA009206NCI NIH HHS U01 CA224166NCI NIH HHS U01 CA233102NIDCR NIH HHS P50 DE026787NIGMS NIH HHS T32 GM008692NIH HHS DP5 OD024576NIH HHS S10 OD028670
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCarcinoma, Squamous CellCell Line, TumorCombined Modality TherapyDose-Response Relationship, RadiationFemaleGene Expression Regulation, NeoplasticGene Knockout TechniquesHead and Neck NeoplasmsImmune Checkpoint InhibitorsInterferon Type ILymphocytesMelanoma, ExperimentalMembrane ProteinsMiceMice, Inbred C57BLImmune Checkpoint InhibitorsInterferon Type IMembrane ProteinsNeoplasm ProteinsRadiopharmaceuticalsSting1 protein, mouseSTING ProteinTpt1 protein, mouseTumor Protein, Translationally-Controlled 1Yttrium-90Yttrium Radioisotopescheckpoint blockadeexternal beam radiotherapyimmune susceptibilitytargeted radionuclide therapytype 1 interferon
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.